Nature Biotechnology Contents: Volume 32 pp 295 - 396

If you are unable to see the message below, click here to view.

Advertisement Powerful reasons to choose Reichert Surface Plasmon Resonance (SPR) systems for your lab SPR technology at a fraction of the cost of the leading competitor. Less expensive without compromising on performance. Low maintenance costs and no service contract necessary. Our SPR team delivers outstanding technical support. Compare for yourself. ReichertSPR.com/advantage TABLE OF CONTENTS April 2014 Volume 32, Issue 4 Editorial News Bioentrepreneur Opinion and Comment Features News and Views Computational Biology Research Careers and Recruitment Advertisement   Kymab is a cutting edge biotechnology company that has created their world class Kymouse™ technology for the development of best in class therapeutic antibodies. If you are an academic investigator and want to learn about how you can work collaboratively with Kymab to generate novel medicines, please visit Kymab Access Subscribe   Facebook   RSS   Recommend to library   Twitter   Advertisement BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities   Advertisement Scientific Data: Credit where credit's due  Get credit for sharing your data! Scientific Data is now accepting Data Descriptor submissions. The Data Descriptor is designed to provide detailed descriptions of datasets: focusing on how these have been produced, by whom, and how they could be reused. Submit yours today!    Editorial Top Genome editing for all   p295 doi:10.1038/nbt.2879 CRISPR-Cas is about to transform how we interrogate genetic variants and model disease. News Top Immune-checkpoint inhibitors march on, now in combinations   pp297 - 299 Cormac Sheridan doi:10.1038/nbt0414-297 Ablynx checkpoint agents lure Merck   p298 Gunjan Sinha doi:10.1038/nbt0414-298 Mitochondrial medicine   p300 Emma Dorey doi:10.1038/nbt0414-300a Leptin therapy gains FDA approval   pp300 - 302 Gunjan Sinha doi:10.1038/nbt0414-300b Epilepsy neurodevice approved   p301 Alli Proffitt doi:10.1038/nbt0414-301 AAV gene therapy continues to woo investors   p302 Barbara Cassasus doi:10.1038/nbt0414-302a Cheerios alert   p302 doi:10.1038/nbt0414-302b Circadian rhythm drug approved   p303 Man Tsuey Tse doi:10.1038/nbt0414-303b Engineered tracheas, corneas and arteries enter clinical testing   pp303 - 304 Michael Eisenstein doi:10.1038/nbt0414-303a Fraunhofer to mine Sanofi microbial collection   p305 Jeffrey L Fox doi:10.1038/nbt0414-305a First royal to have genome sequenced   p305 doi:10.1038/nbt0414-305b Cancer trial assesses clinical benefit of gene-targeted treatment   p306 Alla Katsnelson doi:10.1038/nbt0414-306 Ten large companies join NIH to speed up drug discovery   p307 Jeffrey L Fox doi:10.1038/nbt0414-307a Around the world in a month   p307 doi:10.1038/nbt0414-307b Data Page Drought-tolerant varieties begin global march   p308 Andrew Marshall doi:10.1038/nbt.2875 News Feature Gene editing at CRISPR speed   pp309 - 312 doi:10.1038/nbt.2863 Ease of use, economy and speed of targeting DNA has propelled the CRISPR-Cas system into the spotlight. Now, despite numerous gaps in our knowledge, commercial entities are looking for a piece of the action. Monya Baker reports. Bioentrepreneur Top Datapage Academic-industry partnerships 2013   p313 Brady Huggett doi:10.1038/nbt.2861 Podcast First Rounders: Michael West   p313 doi:10.1038/nbt0414-313 Opinion and Comment Top Correspondence HIV eradication—from Berlin to Boston   pp315 - 316 Paula M Cannon, Donald B Kohn and Hans-Peter Kiem doi:10.1038/nbt.2868 The time is ripe for an ethics of entrepreneurship   pp316 - 318 Christopher Thomas Scott, Emily L Borgelt and Sandra Soo-Jin Lee doi:10.1038/nbt.2867 The third way of umbilical cord blood banking   pp318 - 319 Hung-Chieh Chang doi:10.1038/nbt.2866 The morality of patents on pre-implantation genetic diagnosis   pp319 - 320 David B Resnik doi:10.1038/nbt.2865 Putting cells to sleep for future science   pp320 - 322 Glyn N Stacey and John G Day doi:10.1038/nbt.2869 Features Top A survey of breakthrough therapy designations   pp323 - 330 Saurabh (Rob) Aggarwal doi:10.1038/nbt.2864 As of last month, 41 products have been granted breakthrough therapy designations by the US Food and Drug Administration[mdash]drugs against cancer, hepatitis C and monogenetic diseases predominate. Patents Does CRISPR-Cas open new possibilities for patents or present a moral maze?   pp331 - 333 Philip Webber doi:10.1038/nbt.2843 CRISPR-Cas systems, which enable the production of new artificial genes, synthetic proteins and new transgenic organisms, will challenge patent practices worldwide. Recent patent applications in CRISPR-Cas systems   p334 doi:10.1038/nbt.2883 News and Views Top New models of human immunity   pp335 - 336 Hergen Spits doi:10.1038/nbt.2871 Two humanized mouse models open up a plethora of research applications. See also: Research by Lee et al. | Research by Rongvaux et al. Making light of stress   pp337 - 338 Jefferson Chan and Christopher J Chang doi:10.1038/nbt.2873 A nanoparticle that senses reactive oxygen and nitrogen species in the liver should improve in vivo detection of cellular stress. See also: Research by Shuhendler et al. Cas9 in close-up   pp338 - 340 Erin L Garside and Andrew M MacMillan doi:10.1038/nbt.2872 Structural and biochemical studies elucidate DNA targeting by the Cas9 endonuclease. Research Highlights   p340 doi:10.1038/nbt.2876 Biotechnology JOBS of the week Postdoctoral Research Assistant University of Dundee PhD in Influenza Immunity University of Kent Postdoctoral Research - Aging Bioinformatics Buck Institute for Research on Aging Chair (W3) of Proteomics TU Dresden - Biotechnology Centre (BIOTEC) Research Group Leader in Membrane Biochemistry Max Planck Institute of Molecular Cell Biology and Genetics More Science jobs from Biotechnology EVENT 16 th International Biotechnology Symposium & Exhibition - IBS2014 September 14, 2014 Fortaleza, Brazil More science events from Computational Biology Top Analysis Genome-guided transcript assembly by integrative analysis of RNA sequence data   pp341 - 346 Nathan Boley, Marcus H Stoiber, Benjamin W Booth, Kenneth H Wan, Roger A Hoskins et al. doi:10.1038/nbt.2850 Boley et al. describe an automated approach for integrating multiple types of RNA sequence data to assemble transcripts. Research Top Review CRISPR-Cas systems for editing, regulating and targeting genomes   pp347 - 355 Jeffry D Sander and J Keith Joung doi:10.1038/nbt.2842 Articles Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery   pp356 - 363 E-Chiang Lee, Qi Liang, Hanif Ali, Luke Bayliss, Alastair Beasley et al. doi:10.1038/nbt.2825 Mice engineered to express the entire human variable immunoglobulin region enable rapid isolation of high-affinity antibodies specific for antigens of interest. See also: News and Views by Spits Development and function of human innate immune cells in a humanized mouse model   pp364 - 372 Anthony Rongvaux, Tim Willinger, Jan Martinek, Till Strowig, Sofia V Gearty et al. doi:10.1038/nbt.2858 A mouse bearing multiple human cytokine genes enables in vivo development and function of various human innate immune cell types. See also: News and Views by Spits Real-time imaging of oxidative and nitrosative stress in the liver of live animals for drug-toxicity testing   pp373 - 380 Adam J Shuhendler, Kanyi Pu, Lina Cui, Jack P Uetrecht and Jianghong Rao doi:10.1038/nbt.2838 Semiconducting polymer nanoparticles are used to image toxic reactive oxygen and reactive nitrogen species in live mice. See also: News and Views by Chan & Chang Letters The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells   pp381 - 386 Cole Trapnell, Davide Cacchiarelli, Jonna Grimsby, Prapti Pokharel, Shuqiang Li et al. doi:10.1038/nbt.2859 An algorithm uncovers transcriptome dynamics during differentiation by ordering RNA-Seq data from single cells. Massively parallel functional annotation of 3[prime] untranslated regions   pp387 - 391 Wenxue Zhao, Joshua L Pollack, Denitza P Blagev, Noah Zaitlen, Michael T McManus et al. doi:10.1038/nbt.2851 A method for high-throughput functional testing of 3[prime] UTR sequences uncovers new regulatory elements and effects of noncoding genetic variants. Careers and Recruitment Top Pay increases still healthy for nonfounder executives at private life sciences companies   pp393 - 395 Bruce Rychlik doi:10.1038/nbt.2878 Executive cash compensation data for nonfounders revealed a 3% year-over-year rise. People People   p396 doi:10.1038/nbt.2882 Top Advertisement Partnerships that drive high impact open science  Nature Partner Journals is a new series of online open access journals published in collaboration with world-renowned international partners. Each partnership in the portfolio brings together strong editorial leadership with world-class publication systems to deliver high-quality, peer-reviewed original research.     Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.